Restore Vision Raises $1 billion Series B
Restore Vision Secures ¥1.3 Billion in Pre-Series B Funding to Accelerate Global Development of Gene Therapy for Retinal Diseases raised $1B in Series B financing. Restore Vision Secures ¥1.3 Billion in Pre-Series B Funding to Accelerate Global Development of Gene Therapy for Retinal Diseases is a Digital Health company focused on Accelerate Global Development of Gene Therapy for Retinal Diseases - BRIDGE（ブリッジ）. The new capital is framed around Accelerate Global Development of Gene Therapy for Retinal Diseases - BRIDGE（ブリッジ）.
What it does
Restore Vision Secures ¥1.3 Billion in Pre-Series B Funding to Accelerate Global Development of Gene Therapy for Retinal Diseases is a Digital Health company focused on Accelerate Global Development of Gene Therapy for Retinal Diseases - BRIDGE（ブリッジ）. The business sits in Healthcare & Life Sciences, where funded companies are using fresh capital to deepen product coverage, distribution, or operating capacity.
Traction
Restore Vision Secures ¥1.3 Billion in Pre-Series B Funding to Accelerate Global Development of Gene Therapy for Retinal Diseases - BRIDGE（ブリッジ）. Management framed the new capital around Accelerate Global Development of Gene Therapy for Retinal Diseases - BRIDGE（ブリッジ）.
Trend impact
MD-grade thesis held: available source material is not specific enough to support a non-generic investor-economist read without overclaiming.
Funding history
- April 16, 2026 · Series B · $1 billion · undisclosed investors
Products & services
- Development capability
- News Releases capability
- Restore Vision Inc. Development of gene-agnostic optogenetic capability
- Yusaku Katada, CEO of Restore Vision capability
- Taking advantage of the regulatory landscape in Japan, we are building capability